At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 24, 2026 at 20:00 ET
HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma (ICC), with an IRC-assessed ORR of 42.5% and median OS of 16.6 months. The NDA has been accepted and granted priority review by China's NMPA, positioning fanregratinib as a potential new treatment option in a targeted ICC population.
- Pivotal Phase II study met primary endpoint with IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%) in advanced ICC patients with FGFR2 fusions/rearrangements.
- Median progression-free survival (PFS) was 6.9 months; median overall survival (OS) was 16.6 months.
- NDA for fanregratinib in this indication accepted and granted priority review by China's NMPA in December 2025.
- Drug-related Grade 3+ adverse events occurred in 48.3% of patients; treatment discontinuation due to AEs was only 2.2% with no treatment-related deaths.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access